Molecular profiling revealed 90% PD-L1 expression, multiple oncogenic mutations including SMARCA4 and POLE, and a mutational signature consistent with high tumor mutational burden (TMB), suggesting potential immunogenicity. The gene discussed is CD274; the disease is neoplasm.